---
title: Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates
nct_id: NCT02845089
overall_status: COMPLETED
sponsor: Bristol-Myers Squibb
study_type: OBSERVATIONAL
primary_condition: Lung Cancer
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02845089.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02845089"
ct_last_update_post_date: 2018-03-22
last_seen_at: "2026-05-12T06:50:40.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates

**NCT ID:** [NCT02845089](https://clinicaltrials.gov/study/NCT02845089)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 382
- **Lead Sponsor:** Bristol-Myers Squibb
- **Conditions:** Lung Cancer
- **Start Date:** 2016-02-29
- **Completion Date:** 2017-08-15
- **CT.gov Last Update:** 2018-03-22

## Brief Summary

A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adults 18 years and older at the time of advanced/metastatic NSCLC diagnosis, and currently alive or deceased
* Histologically confirmed diagnosis of advanced/metastatic NSCLC (squamous, non-squamous or NOS) stages IIIB/IV. First diagnosis of advanced/metastatic NSCLC between 01-Jan-2010 and 31-Mar-2014 (currently alive or deceased) with a minimum 12 months of potential observation period available in medical records
* Medical history and treatment data must be available (or obtainable by SI) for chart abstraction from the date of advanced/metastatic diagnosis through most recent patient follow-up/contact. This also includes documentation of treatment by other physicians and inpatient hospital treatments within KSA or the Health Authority of Abu Dhabi (HAAD) system
* Patients must have at least all data on age, gender, date of advanced NSCLC diagnosis, Line of Treatment (LOT) information (agent types and dosage), and date of last follow-up

Exclusion Criteria:

* Patient had enrolled in a cancer treatment-related clinical study at any time after the diagnosis of advanced/metastatic NSCLC
```

## Arms

- **Advanced/Metastatic NSCLC patients from UAE and KSA** — A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)

## Primary Outcomes

- **Patient Demographics at diagnosis with advanced/metastatic NSCLC** _(time frame: at baseline)_
- **Systemic treatments prescribed for NSCLC patients from treatment initiation through discontinuation** _(time frame: approximately 12 months)_
- **Duration of systemic treatments** _(time frame: approximately 12 months)_
- **Distribution of reasons for discontinuing treatment** _(time frame: approximately 12 months)_

## Secondary Outcomes

- **healthcare resource utilization in patients with advanced/metastatic NSCLC** _(time frame: approximately 12 months)_
- **Progression-Free Survival (PFS)** _(time frame: approximately 12 months)_
- **Overall Survival (OS)** _(time frame: approximately 12 months)_
- **Adverse Events (AEs)** _(time frame: approximately 12 months)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02845089.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02845089*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*